4//SEC Filing
Kumar Neil 4
Accession 0001470831-25-000422
CIK 0001743881other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 6:27 PM ET
Size
14.6 KB
Accession
0001470831-25-000422
Insider Transaction Report
Form 4
Kumar Neil
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-12+60,975→ 289,751 total - Tax Payment
Common Stock
2025-12-12$75.15/sh−30,964$2,326,945→ 258,787 total - Sale
Common Stock
2025-12-15$74.60/sh−28,311$2,111,992→ 230,476 total - Sale
Common Stock
2025-12-15$75.24/sh−1,700$127,910→ 228,776 total - Exercise/Conversion
Restricted Stock Units
2025-12-12−60,975→ 60,976 total→ Common Stock (60,975 underlying)
Holdings
- 755,686(indirect: By Trust)
Common Stock
- 4,558,447(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 60,975 shares of Common Stock underlying the Reporting Person's RSUs.
- [F3]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- [F4]Represents the weighted average sale price of the shares sold from $74.12 to $75.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]Represents the weighted average sale price of the shares sold from $75.13 to $75.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- [F7]The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001742485
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 6:27 PM ET
- Size
- 14.6 KB